Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone plus glatiramer acetate versus mitoxantrone in secondary-progressive multiple sclerosis
2009-010661-23Phase 3Terminated
- Sponsor
- Azienda Ospedaliera Universitaria Luigi Vanvitelli
- Start
- Jan 2011
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3 trial of mitoxantrone and glatiramer acetate in multiple sclerosis (MS) (2 arms), sponsored by Azienda Ospedaliera Universitaria Luigi Vanvitelli. Primary endpoints: Confirmed disability progression, Change in EDSS and 1 more. Started Jan 2011; status: terminated.
02
Drugs
mitoxantroneglatiramer acetate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2009-010661-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010661-23.